From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: DCTA

Search articles by EPIC code
EPIC DCTA
views

Directa Plus – trading warning. How much faith to have in its stated 2023 confidence?

Previously writing on company describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA), in October with the shares up to 89.5p I concluded that its recent announcements and above £59 million market cap meant that I retained caution, still avoid/sell. The shares last closed at 83.8p but are currently falling well below 80p on the back of a “trading update”.

EPIC DCTA
views

Directa Plus – interims, is this really ‘a leading producer and supplier maintaining a positive outlook’?

Writing on company which describes itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets” Directa Plus (DCTA) at the start of this month with the shares just below 90p I concluded, ahead of the half-year financial detail, still avoid / sell. So what of the now-announced results and the shares more than 12% lower at 76.5p?

EPIC DCTA
views

Directa Plus – argues “continues to perform strongly”. Does it?

Writing on company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) earlier this week, I noted US patents development and “generating considerable interest”, but what about the financials?. So what of now a “pleased to provide… trading update ahead of the announcement of its half year results for the six months to 30 June 2022 on 29 September”?

EPIC DCTA
views

Directa Plus – US patents development and “generating considerable interest”, but what about the financials?

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has received a Notice of Allowance from the United States Patent and Trademark Office for the grant of a patent covering the Company's G+ embedded polyurethane membrane”, with the offering “generating considerable interest in the US market”. So what of a current 90p share price?

EPIC DCTA
views

Directa Plus – 2021 results, how “comfortable” with forecasts?...

Producer and supplier of graphene nanoplatelets-based products Directa Plus (DCTA) has announced 2021 results emphasising “revenue and profitability which have exceeded consensus market expectations” and “a number of exciting opportunities in our targeted markets”. So what of a current 121.5p share price?...

Page 1 of 3 (29 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments